Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 19/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896240 | 0.94 | SLC9A1 (0.62) | SLC9A1 | |
| SCHEMBL829372 | 0.84 | SLC9A1 (0.50) | SLC9A1 | |
| SCHEMBL828437 | 0.83 | SLC9A1 (0.65) | SLC9A1 | |
| SCHEMBL828939 | 0.83 | SLC9A1 (0.65) | SLC9A1 | |
| SCHEMBL828380 | 0.83 | SLC9A1 (0.49) | SLC9A1 | |
| SCHEMBL829096 | 0.82 | SLC9A1 (0.65) | SLC9A1 | |
| SCHEMBL828551 | 0.82 | SLC9A1 (0.65) | SLC9A1 | |
| SCHEMBL828890 | 0.82 | SLC9A1 (0.65) | SLC9A1 | |
| SCHEMBL829474 | 0.82 | SLC9A1 (0.67) | SLC9A1 | |
| SCHEMBL828299 | 0.81 | SLC9A1 (0.66) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-01-07 | — | — | US | claimed |
| EP-1831192-A4 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-19 | — | — | EP | claimed |
| EP-1831192-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2007-09-12 | — | — | EP | claimed |
| WO-2006071047-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-06 | — | — | WO | claimed |
| US-8143307-B2 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| EP-1831192-B1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2011-08-24 | — | — | EP | disclosed |
| US-20100249064-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS INVOLVING HIGHER MOLECULAR WEIGHT HYALURONAN | UNIVERSITY OF CHICAGO (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-01-07 | — | — | US | disclosed |
| EP-1831192-A4 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009033047-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS INVOLVING HIGHER MOLECULAR WEIGHT HYALURONAN | UNIVERSITY OF CHICAGO (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1831192-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071047-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | TNNI3, TNNT2, SLC9A2 | SLC9A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.